FiercePharma5d
With amped up manufacturing effort, Sanofi and AZ look to avoid Beyfortus shortfalls this year
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
Zacks.com on MSN3d
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...
Sanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market Catalysts
Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...
BioPharma Dive6d
Sanofi readies to meet US demand for RSV antibody
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.
Morningstar7d
Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA
16, 2024 /PRNewswire/ -- Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and ...
Nasdaq3d
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Sanofi recently launched some interesting new products with the most important being novel recombinant factor VIII therapy, Altuviiio and Beyfortus/nirsevimab antibody for respiratory syncytial ...
Stockhouse7d
Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA
16, 2024 /PRNewswire/ -- Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and ...